297 related articles for article (PubMed ID: 30026054)
1. Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment.
Wakasugi H; Takahashi H; Niinuma T; Kitajima H; Oikawa R; Matsumoto N; Takeba Y; Otsubo T; Takagi M; Ariizumi Y; Suzuki M; Okuse C; Iwabuchi S; Nakano M; Akutsu N; Kang JH; Matsui T; Yamada N; Sasaki H; Yamamoto E; Kai M; Sasaki Y; Sasaki S; Tanaka Y; Yotsuyanagi H; Tsutsumi T; Yamamoto H; Tokino T; Nakase H; Suzuki H; Itoh F
Cancer Lett; 2018 Oct; 434():91-100. PubMed ID: 30026054
[TBL] [Abstract][Full Text] [Related]
2. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
Giray BG; Emekdas G; Tezcan S; Ulger M; Serin MS; Sezgin O; Altintas E; Tiftik EN
Mol Biol Rep; 2014 Jul; 41(7):4513-9. PubMed ID: 24595450
[TBL] [Abstract][Full Text] [Related]
3. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
5. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
6. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus and hepatocellular carcinoma at the miRNA level.
Zhang ZZ; Liu X; Wang DQ; Teng MK; Niu LW; Huang AL; Liang Z
World J Gastroenterol; 2011 Jul; 17(28):3353-8. PubMed ID: 21876625
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma.
Pratedrat P; Chuaypen N; Nimsamer P; Payungporn S; Pinjaroen N; Sirichindakul B; Tangkijvanich P
PLoS One; 2020; 15(4):e0232211. PubMed ID: 32330203
[TBL] [Abstract][Full Text] [Related]
9. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
[TBL] [Abstract][Full Text] [Related]
10. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
12. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
Tat Trung N; Duong DC; Tong HV; Hien TTT; Hoan PQ; Bang MH; Binh MT; Ky TD; Tung NL; Thinh NT; Sang VV; Thao LTP; Bock CT; Velavan TP; Meyer CG; Song LH; Toan NL
PLoS One; 2018; 13(4):e0196081. PubMed ID: 29672637
[TBL] [Abstract][Full Text] [Related]
13. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA profile in HBV-induced infection and hepatocellular carcinoma.
Wang G; Dong F; Xu Z; Sharma S; Hu X; Chen D; Zhang L; Zhang J; Dong Q
BMC Cancer; 2017 Dec; 17(1):805. PubMed ID: 29191172
[TBL] [Abstract][Full Text] [Related]
15. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma.
Wang Y; Gao Y; Shi W; Zhai D; Rao Q; Jia X; Liu J; Jiao X; Du Z
Cancer Biomark; 2015; 15(2):171-80. PubMed ID: 25519019
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Regulates Host Gene PPM1A Related to Hepatocellular Carcinoma.
Chavalit T; Nimsamer P; Sirivassanametha K; Anuntakarun S; Saengchoowong S; Tangkijvanich P; Payungporn S
Microrna; 2020; 9(3):232-239. PubMed ID: 31686644
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
[TBL] [Abstract][Full Text] [Related]
18. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.
Zekri AN; Youssef AS; El-Desouky ED; Ahmed OS; Lotfy MM; Nassar AA; Bahnassey AA
Tumour Biol; 2016 Sep; 37(9):12273-12286. PubMed ID: 27271989
[TBL] [Abstract][Full Text] [Related]
19. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR-122.
Liang YJ; Chiou YW; Chiu AP; Shiao MS; Teng W; Lin CW; Cheng ML; Huang YH; Liang KH; Su CW; Lai CY; Chen CL; Wu JC
J Med Virol; 2023 Dec; 95(12):e29325. PubMed ID: 38108211
[TBL] [Abstract][Full Text] [Related]
20. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma.
Morishita A; Fujita K; Iwama H; Chiyo T; Fujihara S; Oura K; Tadokoro T; Mimura S; Nomura T; Tani J; Yoneyama H; Kobayashi K; Kamada H; Guan Y; Nishiyama A; Okano K; Suzuki Y; Himoto T; Shimotohno K; Masaki T
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G401-G409. PubMed ID: 31905024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
